IL245908B - Consequences of pyranochromanil phenol and a pharmaceutical preparation for the treatment of metabolic syndrome or inflammatory disease - Google Patents
Consequences of pyranochromanil phenol and a pharmaceutical preparation for the treatment of metabolic syndrome or inflammatory diseaseInfo
- Publication number
- IL245908B IL245908B IL245908A IL24590816A IL245908B IL 245908 B IL245908 B IL 245908B IL 245908 A IL245908 A IL 245908A IL 24590816 A IL24590816 A IL 24590816A IL 245908 B IL245908 B IL 245908B
- Authority
- IL
- Israel
- Prior art keywords
- pharmaceutical composition
- inflammatory disease
- metabolic syndrome
- phenol derivative
- treating metabolic
- Prior art date
Links
- 208000001145 Metabolic Syndrome Diseases 0.000 title 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 title 1
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000002989 phenols Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
- C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
- C07D493/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D497/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Immunology (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Gastroenterology & Hepatology (AREA)
- Dermatology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20130162909 | 2013-12-24 | ||
| KR1020140181951A KR102344479B1 (ko) | 2013-12-24 | 2014-12-17 | 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물 |
| PCT/KR2014/012688 WO2015099392A1 (ko) | 2013-12-24 | 2014-12-23 | 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL245908A0 IL245908A0 (en) | 2016-08-02 |
| IL245908B true IL245908B (en) | 2020-08-31 |
Family
ID=53788040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL245908A IL245908B (en) | 2013-12-24 | 2016-05-29 | Consequences of pyranochromanil phenol and a pharmaceutical preparation for the treatment of metabolic syndrome or inflammatory disease |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US9783551B2 (enExample) |
| EP (1) | EP3098224B1 (enExample) |
| JP (2) | JP6620096B2 (enExample) |
| KR (1) | KR102344479B1 (enExample) |
| CN (1) | CN105849111B (enExample) |
| AU (1) | AU2014370697B2 (enExample) |
| BR (1) | BR112016011281B1 (enExample) |
| CA (1) | CA2929001C (enExample) |
| CY (1) | CY1121554T1 (enExample) |
| DK (1) | DK3098224T3 (enExample) |
| ES (1) | ES2718878T3 (enExample) |
| HR (1) | HRP20190573T1 (enExample) |
| HU (1) | HUE043902T2 (enExample) |
| IL (1) | IL245908B (enExample) |
| MX (1) | MX374944B (enExample) |
| NZ (1) | NZ720328A (enExample) |
| PL (1) | PL3098224T3 (enExample) |
| PT (1) | PT3098224T (enExample) |
| SG (1) | SG11201604371PA (enExample) |
| TW (1) | TWI585093B (enExample) |
| WO (1) | WO2015099392A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102344479B1 (ko) * | 2013-12-24 | 2021-12-29 | 주식회사 글라세움 | 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물 |
| SG11201811796SA (en) * | 2016-06-29 | 2019-02-27 | Glaceum Inc | Optically active pyranochromenyl phenol derivative and pharmaceutical composition comprising same |
| JP6810275B2 (ja) | 2016-10-04 | 2021-01-06 | グラセウム・インコーポレイテッド | ３−フェニル−２，３，４，８，９，１０−ヘキサヒドロピラノ［２，３−ｆ］クロメン誘導体およびその光学異性体の合成方法 |
| TWI804600B (zh) | 2018-04-03 | 2023-06-11 | 南韓商格雷森伍股份有限公司 | 3-苯基-2,8-二氫吡喃[2,3-ƒ]苯并哌喃衍生物的合成方法 |
| KR20190116099A (ko) | 2018-04-03 | 2019-10-14 | 주식회사 글라세움 | 3-페닐-2,8-디히드로피라노[2,3-f]크로멘 유도체 및 이를 포함하는 약학적 조성물 |
| KR20200105198A (ko) | 2019-02-28 | 2020-09-07 | 주식회사 글라세움 | 신경계 질환의 예방 또는 치료용 약학적 조성물 |
| KR102692932B1 (ko) | 2019-07-30 | 2024-08-07 | 주식회사 글라세움 | 2-((6-(히드록시메틸)크로멘-5-일)옥시)-1-페닐에타논 유도체의 합성 방법 |
| KR20220166203A (ko) | 2021-06-08 | 2022-12-16 | 주식회사 글라세움 | 퇴행성 안질환의 예방 또는 치료용 약학적 조성물 |
| CN113616548B (zh) * | 2021-09-02 | 2023-04-28 | 河南科技大学 | 一种水溶性光甘草定包合物及其制备方法 |
| US20250250279A1 (en) | 2022-04-12 | 2025-08-07 | Glaceum Inc. | METHOD FOR SYNTHESIZING 3-PHENYL-2,3,4,8,9,10-HEXAHYDROPYRANO[2,3-f]CHROMENE DERIVATIVES |
| CN114903879B (zh) * | 2022-06-23 | 2023-10-31 | 东北大学 | 3-烃基苯酚衍生物在制备预防或治疗高脂血症及相关代谢性疾病产品中的用途 |
| WO2024151017A1 (ko) | 2023-01-12 | 2024-07-18 | 주식회사 글라세움 | 퇴행성 골관절염의 예방 또는 치료용 약학적 조성물 |
| KR20250081177A (ko) | 2023-11-29 | 2025-06-05 | 한국화학연구원 | Hsg4112 r형을 유효성분으로 포함하는 반려동물의 비만 예방, 개선 또는 치료용 조성물 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1440688A4 (en) | 2001-10-11 | 2005-11-30 | Kaneka Corp | PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR LIGANDS AND METHOD OF MANUFACTURING THE SAME |
| KR100565423B1 (ko) * | 2003-10-20 | 2006-03-30 | 빅 바이오 주식회사 | 이소플라반 유도체 또는 이소플라벤 유도체의 제조방법 |
| JP2006008604A (ja) * | 2004-06-25 | 2006-01-12 | Kuraray Co Ltd | イソフラバン誘導体の製造方法 |
| WO2007058480A1 (en) | 2005-11-16 | 2007-05-24 | Md Bioalpha Co., Ltd. | Composition having effect on treatment and prevention of diseases syndrome treatment with glabridin |
| KR102344479B1 (ko) * | 2013-12-24 | 2021-12-29 | 주식회사 글라세움 | 피라노크로메닐페놀 유도체, 및 대사증후군 또는 염증 질환 치료용 약학 조성물 |
-
2014
- 2014-12-17 KR KR1020140181951A patent/KR102344479B1/ko active Active
- 2014-12-23 EP EP14873860.2A patent/EP3098224B1/en active Active
- 2014-12-23 HU HUE14873860 patent/HUE043902T2/hu unknown
- 2014-12-23 DK DK14873860.2T patent/DK3098224T3/da active
- 2014-12-23 CA CA2929001A patent/CA2929001C/en active Active
- 2014-12-23 JP JP2016540481A patent/JP6620096B2/ja active Active
- 2014-12-23 HR HRP20190573TT patent/HRP20190573T1/hr unknown
- 2014-12-23 PT PT14873860T patent/PT3098224T/pt unknown
- 2014-12-23 SG SG11201604371PA patent/SG11201604371PA/en unknown
- 2014-12-23 PL PL14873860T patent/PL3098224T3/pl unknown
- 2014-12-23 MX MX2016008429A patent/MX374944B/es active IP Right Grant
- 2014-12-23 WO PCT/KR2014/012688 patent/WO2015099392A1/ko not_active Ceased
- 2014-12-23 ES ES14873860T patent/ES2718878T3/es active Active
- 2014-12-23 BR BR112016011281-4A patent/BR112016011281B1/pt active IP Right Grant
- 2014-12-23 NZ NZ720328A patent/NZ720328A/en unknown
- 2014-12-23 AU AU2014370697A patent/AU2014370697B2/en active Active
- 2014-12-23 CN CN201480070935.5A patent/CN105849111B/zh active Active
- 2014-12-23 US US15/037,230 patent/US9783551B2/en active Active
- 2014-12-24 TW TW103145316A patent/TWI585093B/zh active
-
2016
- 2016-05-29 IL IL245908A patent/IL245908B/en active IP Right Grant
-
2018
- 2018-03-23 JP JP2018056783A patent/JP2018135343A/ja active Pending
-
2019
- 2019-04-16 CY CY20191100423T patent/CY1121554T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL245908A0 (en) | Consequences of pyranochromanil phenol and a pharmaceutical preparation for the treatment of metabolic syndrome or inflammatory disease | |
| SI2986304T1 (sl) | Farmacevtski sestavek, postopki za zdravljenje in njegove uporabe | |
| BR112015001098A2 (pt) | composto, composição farmacêutica e método para o tratamento de uma condição de doença. | |
| IL243042A0 (en) | Consequences of aminotriazine and a pharmaceutical preparation containing it | |
| SMT201900684T1 (it) | Composizione farmaceutica combinata | |
| BR112015002738A2 (pt) | composto , e , composição farmacêutica | |
| PT2640205T (pt) | Sistema para fumar aquecido elétrico compreendendo, pelo menos, duas unidades | |
| ZA201403276B (en) | Low dose pharmaceutical composition | |
| ZA201509307B (en) | Pharmaceutical composition, preparation and uses thereof | |
| LT3735962T (lt) | Farmacinė kompozicija, apimanti fosfatus surišančias daleles | |
| EP3012292A4 (en) | PROCESSING AGENTS AND COMPOSITION | |
| EP2990419A4 (en) | Preventive or therapeutic agent for inflammatory disease | |
| EP2981554A4 (en) | Methods and compositions for treating and preventing disease associated with avb8 integrin | |
| SG11201601477VA (en) | Pharmaceutical composition | |
| GB201320932D0 (en) | Topical pharmaceutical composition | |
| BR112014032501A2 (pt) | composto, e, composição farmacêutica. | |
| EP3020399A4 (en) | PHARMACEUTICAL COMPOSITION FOR THE PREVENTION AND TREATMENT OF CANCER | |
| HUE051902T2 (hu) | Duális újrafelvétel inhibitort tartamazó gyógyászati készítmény és eljárás annak elõállítására | |
| ZA201509091B (en) | Antivirally effective pharmaceutical composition | |
| HUP1300496A2 (hu) | Stabil kombinációs gyógyszerkészítmény | |
| IL244365A0 (en) | pharmaceutical preparation | |
| SG11201600119PA (en) | Compound and methods for treating long qt syndrome | |
| EP2992890A4 (en) | Pharmaceutical composition | |
| IL284405A (en) | Pharmaceutical composition, preparation and uses thereof | |
| EP2815756A4 (en) | COMPOSITION FOR THE PREVENTION, TREATMENT OR TREATMENT OF METABOLIC SYNDROME |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed |